| Symbol
| CDK6
| contributors: mct/npt - updated : 26-09-2019
|
| HGNC name
| cyclin-dependent kinase 6
|
| HGNC id
| 1777
|
| corresponding disease(s)
|
MCPH12
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
may link the TP53 and RB1 tumor suppressor pathways to medulloblastoma pathomechanisms | | tumoral
|
| translocation
|
|
| |
dysregulated by translocation (2;7)(p12;q21-22 ) in spleen marginal zone lymphoma and non-Hodgkin lymphoma | | tumoral
|
| translocation
|
|
|
in B-cell lymphoproliferative disorders ( | | tumoral
|
|
| --over
|
| |
dramatically and selectively elevated in PARK2-expressing breast cancer cells ( | | tumoral
|
|
| --over
|
| |
in lymphoid malignancies | |
| Susceptibility
|
to rheumatoid arthritis |
Variant & Polymorphism
| 
| |
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | hemopathy | | |
| specific therapeutic target in human lymphoid malignancies | | cancer | hemopathy | | |
| potential therapeutic target in human lymphoid malignancies | | cancer | hemopathy | | |
| treatment of Burkitt lymphoma cell lines with a CDK4/6 inhibitor not only caused cell cycle arrest but, unexpectedly, induced apoptosis |
| | | |